1. Bakuchiol possesses anti-tumor,and anti-helmenthic properties.
2. Bakuchiol has cytotoxic activity, mainly due to its DNA polymerase1 inhibiting activity.
3. Bakuchiol has anti-bacterial activity against oral pathogens, has great potential for use in food additives and mouthwash for preventing and treating dental caries.
1. Monotropein has anti-inflammatory activity, it exerts protective effects against IL-1β-induced apoptosis and catabolic responses on osteoarthritis chondrocytes.
2. Monotropein contributes to the antinociceptive and anti-inflammatory action of Morinda officinalis root, monotropein (at 20, 30 mg/kg/d, p.o.) can significantly reduce stretching episodes and prolong action time in mice, it also can significantly reduce acute paw edema by carrageenan in rats.
3. Monotropein can increase osteoblastic bone formation and prevent bone loss in ovariectomized mice, it may serve as a new candidate or a leading compound for antiosteoporosis.
1. Velutin has strong anti-inflammatory activity, it can effectively inhibit the expression of proinflammatory cytokines TNF-α and IL-6 in low micromole levels by inhibiting NF-κB activation and p38 and JNK phosphorylation.
2. Velutin exhibits the strongest effects in reducing both TNF-α and IL-6 dose-dependently in the two type cells, it also strongly inhibits NF-κB activation.
3. Velutin controls HIF-1α activity during PgLPS-activated osteoclastogenesis probably through modulation of the NF-κB pathway, perhaps it could be used therapeutically to prevent bone loss seen in periodontitis.
4. Velutin and betulinic acid can induce apoptosis in tumor cells.
1. Harpagoside has anti-inflammatory effects, it blocks lipopolysaccharide (LPS)-induced bone loss in an inflammatory osteoporosis model, and it does not prevent ovariectomy-mediated bone erosion in a postmenopausal osteoporosis model.
2. Harpagoside dose-dependently inhibits LPS-stimulated NF-kappaB promoter activity in a gene reporter assay in RAW 264.7 cells, it suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation.
3. Harpagoside may lead to a partial prevention of obesity-induced atherosclerosis by attenuating inflammatory responses.
4. Harpagoside attenuates the MPTP/MPP + induced dopaminergic neurodegeneration and movement disorder mainly through elevating glial cell line-derived neurotrophic factor.
5. Harpagoside exerts neuroprotection effect and ameliorates learning and memory deficit appears to be associated, at least in part, with up-regulation of brain-derived neurotrophic factor (BDNF) content as well as activating its downstream signaling pathways, e.g., MAPK/PI3K pathways; it has potential to be a therapeutic agent against Alzheimer’s disease (AD).
1. Vitamin D3 induces changes in human PBMCs can be described by transcriptomic and serum biomarkers and allow a segregation into high and low responders.
2. Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes.
3. Supplemental calcium and Vitamin D3 may increase TGFβ1 expression and shift TGFα expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients.